The Journal of Neuroscience, October 8, 2008, 28(41):10404-10414; doi:10.1523/JNEUROSCI.1618-08.2008
Previous Article | Next Article 
Behavioral/Systems/Cognitive
D-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801
Francesco Errico,1 *
Silvia Rossi,2,3 *
Francesco Napolitano,1
Valeria Catuogno,1
Enza Topo,4
Gilberto Fisone,5
Antimo D'Aniello,4
Diego Centonze,2,3 and
Alessandro Usiello1,6
1Laboratory of Behavioural Neuroscience, Centro Ingegneria Genetica Biotecnologie Avanzate, 80145 Naples, Italy, 2Clinica Neurologica, Università Tor Vergata, 00133 Rome, Italy, 3Centro Europeo per la Ricerca sul Cervello/Fondazione Santa Lucia, 00179 Rome, Italy, 4Department of Neurobiology, Stazione Zoologica "A. Dohrn," 80121 Naples, Italy, 5Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden, and 6Department of Health Science, Università del Molise, 86100 Campobasso, Italy
Correspondence should be addressed to Alessandro Usiello, CEINGE Biotecnologie Avanzate, Via ComunaleMargherita 482, 80145 Naples, Italy. Email: usiello{at}ceinge.unina.it
Since their discovery in the mammalian CNS, D-aspartate and D-serine have aroused a strong interest with regard to their role as putative neuromodulatory molecules. Whereas the functional role of D-serine as an endogenous coagonist of NMDA receptors (NMDARs) has been elucidated, the biological significance of D-aspartate in the brain is still mostly unclear. In the present study, we demonstrated that nonphysiological high levels of D-aspartate (1) increased in vivo NMDAR activity, (2) attenuated prepulse inhibition deficits induced by amphetamine and MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine hydrogen maleate], (3) produced striatal adaptations of glutamate synapses resembling those observed after chronic haloperidol treatment, and (4) enhanced hippocampal NMDAR-dependent memory. This evidence was obtained using two different experimental strategies that produced an abnormal increase of endogenous D-aspartate levels in the mouse: a genetic approach based on the targeted deletion of the D-aspartate oxidase gene and a pharmacological approach based on oral administration of D-aspartate. This work provides in vivo evidence of a neuromodulatory role exerted by D-aspartate on NMDAR signaling and raises the intriguing hypothesis that also this D-amino acid, like D-serine, could be used as a therapeutic agent in the treatment of schizophrenia-related symptoms.
Key words: D-aspartate; NMDA receptors; schizophrenia; synaptic plasticity; prepulse inhibition; spatial memory; D-serine
Received Aug. 14, 2008;
accepted Sept. 4, 2008.
Correspondence should be addressed to Alessandro Usiello, CEINGE Biotecnologie Avanzate, Via ComunaleMargherita 482, 80145 Naples, Italy. Email: usiello{at}ceinge.unina.it
This article has been cited by other articles:

|
 |

|
 |
 
G. Martella, A. Tassone, G. Sciamanna, P. Platania, D. Cuomo, M. T. Viscomi, P. Bonsi, E. Cacci, S. Biagioni, A. Usiello, et al.
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine
Brain,
September 1, 2009;
132(9):
2336 - 2349.
[Abstract]
[Full Text]
[PDF]
|
 |
|